Beyond Cochlear Implants: Can Auditory Brainstem Implants Restore Hearing?
"Innovative Approach Combines ABI and CI for Enhanced Hearing in Children with Nerve Deficiencies."
For children born with or who acquire profound hearing loss due to cochlear nerve deficiencies, traditional cochlear implants (CIs) may not be enough. The auditory brainstem implant (ABI) is designed to directly stimulate the brainstem, bypassing the damaged auditory nerve. While ABIs have been used for decades, a new approach combines the ABI with a contralateral CI to maximize auditory input and improve outcomes.
A recent study has explored this combined approach in pediatric patients, focusing on those who initially received CIs without significant benefit. This research offers insights into how the brain adapts to and utilizes signals from both devices, potentially unlocking synergistic effects that enhance overall hearing and speech development.
This article delves into the findings of this study, examining the impact of combined ABI and CI on auditory perception and speech production in children. It addresses the critical questions surrounding patient selection, timing of intervention, and the potential for improved quality of life.
Current Impact
Auditory brainstem implants may offer a hearing-rehabilitation option for people whose cochlea or cochlear nerve cannot support a cochlear implant. Their potential impact is therefore concentrated among patients with profound hearing loss and limited anatomical alternatives. Because outcomes can vary, the device should be understood as a specialized intervention rather than a universal replacement for standard hearing technologies.
Established Approaches
Cochlear implantation remains an established approach for many people with severe to profound sensorineural hearing loss. An auditory brainstem implant is considered when anatomical limitations make cochlear implantation unsuitable. This distinction means that ABI treatment addresses a narrower clinical situation and does not eliminate the limitations associated with direct brainstem stimulation.
From Cochlea to Brainstem
Cochlear implant development included a first human implantation by William House and John Doyle in 1961, followed by FDA approval in 1984. William F. House developed the auditory brainstem implant in 1979 for patients with neurofibromatosis type 2 (NF2). Historical accounts describe that early ABI as a single ball electrode used in one NF2 patient, later developing over four decades into a multichannel device for selected non-tumor patients and deaf children.
Unlocking Potential: How ABI and CI Work Together
The study, conducted as a retrospective case review at a tertiary referral center, focused on four children with cochlear nerve deficiency. These children had initially undergone cochlear implantation but showed limited progress. As a result, they received an ABI in the ear contralateral to their existing CI.
- Improved Auditory Perception: Three out of four subjects demonstrated better auditory perception when using both their CI and ABI compared to using either device alone.
- Subjective Improvement: The fourth subject, while having only preliminary data, subjectively performed better with both devices.
- CI Performance Over Time: The study noted continued improvement in CI performance over time, even when initial benefits were not apparent before ABI implantation. This suggests a potential synergistic effect between ABI and CI or the brain's adaptive capacity.
Evolving Evidence
Recent reviews continue to examine how auditory brainstem implants can serve patients who are not suitable candidates for cochlear implantation. The field remains focused on patient selection, surgical approaches, device performance, and long-term auditory benefit. As with other specialized neuroprosthetic treatments, interpretation of newer findings requires attention to the specific anatomy and clinical population studied.
Limits and Failures
A cochlear implant may fail or become infeasible when conditions such as chronic otomastoiditis cause irreversible cochlear ossification. One case report described ABI implantation as a salvage option in that setting, but reported only limited, functionally useful auditory benefit. More broadly, ABIs are intended for patients who are anatomically or radiologically unsuitable for cochlear implants, not as a routine substitute when a cochlear implant remains viable.
ABI Versus CI
A cochlear implant stimulates the auditory pathway through the cochlea and auditory nerve, whereas an auditory brainstem implant stimulates the brainstem. The two devices therefore address different anatomical problems: cochlear implants are generally considered when the auditory nerve is usable, while ABIs are considered when the nerve or cochlear structures are damaged or unsuitable. Their appropriate use depends on the patient's specific anatomy and clinical needs.
New Horizons in Pediatric Hearing Restoration
This case series highlights the potential benefits of combining ABI and CI in children with cochlear nerve deficiencies. While more research is needed, these findings suggest that this approach can significantly improve auditory perception and speech development.
A Specialized Solution
An auditory brainstem implant is a surgically implanted central neural auditory prosthesis for people with profound sensorineural hearing loss who lack an anatomically intact cochlear nerve or implantable cochlea. It can provide hearing sensations when the auditory nerve is damaged, but reported outcomes are typically much poorer than those of cochlear implant recipients. The evidence therefore supports ABI as a specialized alternative for carefully selected patients rather than an equivalent replacement for cochlear implantation.
Expanding Demand
A 2026 market report describes increasing demand for ABIs because they may be the only viable hearing-rehabilitation technology for profound deafness caused by conditions that destroy or render the cochlea or cochlear nerve non-functional. Another 2026 report characterizes the global market as highly concentrated, with Cochlear Limited, MED-EL Medical Electronics, and Oticon Medical collectively controlling more than 75% of global market share in 2025. These industry projections describe commercial momentum, but they do not by themselves establish improved clinical outcomes.
Anatomical Access
The central systemic challenge addressed by an auditory brainstem implant is anatomical ineligibility for cochlear implantation. The device is designed to provide hearing sensations to deaf patients whose anatomy prevents conventional cochlear implantation. This makes ABI access dependent on specialized assessment and treatment pathways for patients with profound hearing loss and relevant anatomical constraints.
Individualized Benefit
For some patients, an auditory brainstem implant may represent an option when cochlear implantation is not anatomically possible. The practical value of the device is likely to differ between individuals, so expectations should be framed around potential hearing sensation and functional benefit rather than guaranteed restoration of normal hearing. Decisions are best considered in the context of the patient's anatomy, diagnosis, and rehabilitation needs.
The study also underscores the importance of considering individual patient factors and the timing of intervention. Further research should explore the optimal criteria for patient selection and the long-term outcomes of combined ABI and CI use.
As technology advances, the integration of ABI and CI offers a promising avenue for restoring hearing in children who are not candidates for traditional cochlear implantation. By understanding how these devices interact and how the brain adapts, we can unlock new possibilities for improving the quality of life for these children.